XLO
Xilio Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.33 / 10
Netural
Capital flows are positive (score 7.88/10) with overall and extra-large inflows leaning bullish, even as medium and large patterns show weakness. Analyst sentiment is unanimously bullish (1 Buy, 0 others) but lightly covered, adding limited conviction despite a perfect historical win rate.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-08-06
InstitutionLeerink Partners
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for XLO?
- XLO holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.33/10 (Netural).
